Last reviewed: June 19, 2026

Last updated: June 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Women considering semaglutide or other GLP-1 medications while trying to conceive face an important decision: current evidence suggests GLP-1 receptor agonists should be discontinued at least 2-3 months before attempting pregnancy, though weight loss achieved beforehand may improve fertility outcomes. PlexusDx helps patients understand this timeline and explore treatment options that align with family planning goals.

How GLP-1 Medications Affect Fertility and Pregnancy Outcomes

GLP-1 receptor agonists like semaglutide work by slowing stomach emptying and signaling fullness to the brain—mechanisms unrelated to reproductive hormones. However, animal studies have shown mixed results regarding fetal development, and human pregnancy data remains limited because pregnant women are typically excluded from clinical trials. The FDA classifies semaglutide as Category C for pregnancy, meaning animal studies have shown potential risks but human evidence is insufficient. Medical organizations recommend discontinuing GLP-1 therapy before conception to eliminate theoretical exposure during critical fetal development windows.

Paradoxically, achieving significant weight loss before pregnancy can improve fertility and reduce pregnancy complications. Women with elevated BMI experience higher rates of irregular ovulation, gestational diabetes, and preeclampsia; losing even 5–10% of body weight can restore ovulation patterns and reduce these risks substantially. This creates a compelling case for using semaglutide strategically: treat for weight loss now, pause before conception attempts, and enter pregnancy at a lower baseline weight. PlexusDx patients who plan family expansion benefit from this two-phase approach with personalized guidance.

Timeline for Stopping GLP-1 Before Conception Attempts

Reproductive endocrinologists and fertility specialists recommend discontinuing semaglutide 2–3 months before attempting to conceive. This washout period allows the medication to clear from your system and normalizes metabolic signaling during the months when egg quality and reproductive hormone cycles are most critical. If you've been taking semaglutide weekly, total body clearance takes approximately 4 weeks; the 2–3 month buffer provides safety margin and allows your body to re-establish baseline appetite regulation naturally. Starting this conversation with your obstetrician or fertility specialist 3–4 months before your target conception date ensures adequate planning time.

During the washout period, weight maintenance becomes the primary goal rather than continued weight loss. Many patients experience appetite rebound after discontinuing GLP-1 therapy; preparing for this shift with behavioral strategies—scheduled meals, increased protein intake, mindful eating practices—helps preserve the weight loss achieved during active treatment. PlexusDx recommends connecting with a registered dietitian during this transition to sustain your health gains while naturally rebuilding hunger signals that support a normal menstrual cycle and ovulation.

Metabolic Improvements That Support Conception Success

Weight loss initiated by semaglutide creates metabolic advantages that extend beyond the treatment period itself. Women who reach a healthier weight before conception show improved insulin sensitivity, better blood sugar stability, and normalized reproductive hormone profiles—changes that persist even after GLP-1 therapy ends. Research demonstrates that a 5–10% weight loss can restore regular menstrual cycles in women with polycystic ovary syndrome (PCOS), a condition affecting up to 10% of reproductive-age women and a leading cause of infertility. By achieving meaningful weight loss during GLP-1 treatment, you're positioning your body for optimal fertility regardless of medication status.

PlexusDx's Precision Peptide Genetic Test identifies individual metabolic vulnerabilities across 14 pathways, including genetic variants affecting appetite regulation (GLP1R rs6923761), energy storage (FTO rs9939609), and satiety signaling (GIPR rs1800437). Understanding your genetic predispositions helps explain your baseline metabolism and clarifies why semaglutide may be particularly effective for your weight loss—insights that prove valuable as you transition off medication and plan the conception phase of your family timeline.

Planning Semaglutide Treatment Around Your Conception Goals

If you're considering semaglutide and planning to conceive within 12 months, timeline matters significantly. A reasonable approach: start semaglutide now if you have 6+ months before your target conception date, allowing 4–6 months of active treatment followed by the recommended 2–3 month washout. This sequence delivers meaningful weight loss (typically 10–20% of body weight at sustained doses), preserves those gains as you discontinue the medication, and positions you for conception during the normalization period. Your PlexusDx provider can help establish dose progression and duration based on your starting weight and conception timeline.

Transparency with all your healthcare providers—your primary care doctor, fertility specialist, and obstetrician—ensures coordinated, safe planning. Mention your conception timeline when starting semaglutide, document your treatment start date, and schedule a pre-conception visit 3 months before attempting pregnancy to discuss cessation timing and any additional fertility workup. PlexusDx Semaglutide Injection starts at $149/month without membership fees or insurance requirements, making it accessible for patients integrating weight loss into comprehensive family planning. Your dose may need to go up; your price won't.

Conception-Focused Alternatives If You Cannot Pause GLP-1 Therapy

Some patients face circumstances requiring continued weight management through the conception phase—for example, women with severe obesity, metabolic syndrome, or previous stillbirth linked to maternal weight. In these rare cases, consultation with maternal-fetal medicine specialists who have managed GLP-1-exposed pregnancies is essential; some reproductive centers now track pregnancy outcomes in women who continue GLP-1 therapy, though this remains off-label and requires careful informed consent. This scenario demands individualized decision-making with your full healthcare team, weighing the theoretical risks of medication exposure against the documented risks of uncontrolled weight in pregnancy.

If pregnancy occurs unexpectedly while taking semaglutide, immediate contact with your obstetrician is critical—not because GLP-1 exposure guarantees harm, but because early pregnancy management benefits from awareness of all exposures and appropriate fetal monitoring. PlexusDx prioritizes providing accurate information so you can make informed choices; we encourage patients planning pregnancy to discuss GLP-1 use explicitly with fertility and obstetric specialists who can assess individual risk factors.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I stay on semaglutide while trying to conceive?

Current medical guidance recommends discontinuing GLP-1 medications 2–3 months before attempting conception due to limited human pregnancy data and animal study findings. Discuss this timeline with your fertility specialist or obstetrician based on your individual health situation. If you cannot safely pause treatment, specialized maternal-fetal medicine consultation is necessary.

How much weight can I lose before needing to stop semaglutide?

Most patients experience 10–20% weight loss at therapeutic doses over 4–6 months, though individual results vary based on genetics, lifestyle, and baseline metabolism. PlexusDx's Precision Peptide Genetic Test identifies your personalized metabolic pathway to optimize treatment duration and expected weight loss magnitude before your planned conception washout period begins.

Will I regain weight after stopping semaglutide before trying to conceive?

Weight rebound typically ranges from 10–20% of weight lost if appetite regulation reverts to pre-treatment baseline. Strategic dietary planning, structured meal timing, and behavioral support during the post-treatment washout period help minimize regain. Working with a registered dietitian during months 2–3 after discontinuation improves weight maintenance outcomes.

Does PlexusDx semaglutide treatment cost change if I need to adjust my dose timeline?

PlexusDx Semaglutide Injection costs start at $149/month regardless of dose progression or treatment duration. Your dose may need to go up; your price won't. All medications are dispensed from licensed 503A compounding pharmacies, require no insurance, and qualify for HSA/FSA accounts.

How does PlexusDx genetic testing help with conception planning?

The Precision Peptide Genetic Test ($99 add-on after your first treatment month) maps 14 metabolic pathways and identifies variants affecting appetite (GLP1R rs6923761), satiety (GIPR rs1800437), and fat storage (FTO rs9939609). These insights help predict your semaglutide response timeline, optimize treatment duration before your conception washout period, and explain your baseline metabolic behavior as you transition off medication.

What if my fertility specialist recommends stopping semaglutide sooner than planned?

Reproductive specialists may recommend earlier discontinuation based on ovulation monitoring, hormone levels, or individual circumstances. PlexusDx supports flexible treatment pausing—no penalty, no membership commitment required. Work with your fertility team's timeline while maintaining PlexusDx support for post-treatment weight management strategies.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

learn